Kryxana contains ribociclib, a targeted oral medication used in the treatment of certain types of advanced breast cancer. It belongs to a class of drugs known as CDK4 and CDK6 inhibitors, which are designed to block specific enzymes involved in cancer cell growth. Kryxana is typically used in combination with hormonal therapy in postmenopausal women and men whose cancers are hormone receptor positive and HER2 negative.

This treatment has significantly improved progression-free survival in patients with advanced breast cancer, offering a more personalized and precise approach to cancer care.

Mechanism of Action

Ribociclib works by inhibiting two key proteins called cyclin-dependent kinase 4 and 6, which are crucial for cell cycle progression from the G1 phase to the S phase. In many hormone receptor positive breast cancers, these kinases are overactive, leading to uncontrolled cell division.

By blocking these enzymes, ribociclib causes cancer cells to slow down or stop dividing, which helps control tumor growth. It acts synergistically with endocrine therapy by halting cancer progression that is driven by hormone signals.

Uses

Kryxana is used primarily for the treatment of:

• Hormone receptor positive, HER2 negative advanced or metastatic breast cancer

• Used in combination with an aromatase inhibitor (such as letrozole) as initial endocrine-based therapy

• Also used with fulvestrant in women who have received prior endocrine therapy

  Adverse Effects

  Like all cancer treatments, Kryxana may cause side effects, which can range from mild to more serious. Most are manageable with routine monitoring and supportive care.

  Common Side Effects

  • Fatigue and weakness

  • Nausea and vomiting

  • Diarrhea or constipation

  • Hair thinning

  • Decreased appetite

  • Headache

  • Rash